



Kesten, J., Ward, Z. D., Hancock, E., Ayres, R., Neale, J., Hussey, D., Hickman, M., & Vickerman, P. T. (2020). Letter to editor: Response to Commentary on Hancock et al. (2020): Low dead space syringes are just one component of an integrated package of care needed to tackle HCV and social exclusion among people who inject drugs. *Addiction*. <https://doi.org/10.1111/add.15150>

Peer reviewed version

Link to published version (if available):
[10.1111/add.15150](https://doi.org/10.1111/add.15150)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Wiley at <https://onlinelibrary.wiley.com/doi/full/10.1111/add.15150?af=R>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Letter to Editor

Response to: Commentary on Hancock et al. (2020): Low dead space syringes are just one component of an integrated package of care needed to tackle HCV and social exclusion among people who inject drugs

Kesten, Joanna; NIHR ARC West, University Hospitals Bristol NHS Foundation Trust; University of Bristol, NIHR HPRU in Behavioural Science and Evaluation, Population Health Sciences, Bristol Medical School

Ward, Zoe; University of Bristol, Population Health Sciences, Bristol Medical School, Bristol, UK
Hancock, Elizabeth; Source Health Economics, London, UK

Ayres, Rachel; Bristol Drugs Project, Bristol, UK

Neale, Jane; Bristol Drugs Project, Bristol, UK

Deborah Hussey, Deborah; Bristol Drugs Project, Bristol, UK

Hickman, Matthew; University of Bristol, NIHR HPRU in Behavioural Science and Evaluation, Population Health Sciences, Bristol Medical School, Bristol, UK

Vickerman, Peter; University of Bristol, NIHR HPRU in Behavioural Science and Evaluation, Population Health Sciences, Bristol Medical School, Bristol, UK

Corresponding author: Joanna Kesten, jo.kesten@bristol.ac.uk, NIHR ARC West, University Hospitals Bristol NHS Foundation Trust 9th Floor, Whitefriars, Lewins Mead, Bristol BS1 2NT

Declaration of interests

None.

Acknowledgements

E.H.'s MSc was funded by Decision Resources Group and PHMR, under which initial work for the original project was undertaken. The original study this letter relates to was funded in part by the NIHR Health Protection Research Unit in Behavioural Science and Evaluation at University of Bristol, in partnership with Public Health England (PHE). The views expressed are those of the author and not necessarily those of the NIHR, the Department of Health and Social Care, or PHE. JK, MH, ZW and PV acknowledge support from the NIHR Health Protection Research Unit in Behavioural Science and Evaluation at University of Bristol. PV was partially supported by the National Institute for Drug Abuse [R01 DA037773]. JK is partly funded by National Institute for Health Research Applied Research Collaboration West (NIHR ARC West) at University Hospitals Bristol NHS Foundation Trust. RA, JN and DH would like to thank Bristol Drugs Project for giving staff time to support their contribution to this letter.

Keywords: cost effectiveness, hepatitis c, low dead space syringes, modelling, needle and syringe programmes, people who inject drugs

Dear Editor,

We read with interest Platt et al.'s commentary¹ on our economic analysis² and agree with many of the points raised; particularly the urgent need to '*avert the growing health crisis faced by [people who inject drugs] PWID in the United Kingdom*'. We agree that the provision of detachable low dead space syringes (LDSS) is one of several diverse strategies needed to address hepatitis C virus (HCV) transmission, and more broadly, to reduce social exclusion and health and social inequalities among PWID.

We show in economic models that replacing detachable high dead space syringes (HDSS) with detachable LDSS at needle and syringe programmes (NSP) is a cost-saving approach to reducing HCV transmission among PWID. This research forms part of a multi-disciplinary body of evidence supporting the roll out of LDSS. In addition, we have previously demonstrated that LDSS use is associated with reduced HCV risk in the UK, have shown why some PWID use LDSS and some do not,³ and critically shown that NSPs in general are a highly cost-effective way of reducing the spread of HCV among PWID⁴.

We agree that other initiatives are needed to deal with the added risks associated with structural disablers such as homelessness and incarceration. Nevertheless, in the context of funding cuts to services across the health and social care landscape, commissioners and policy makers need clear evidence on cost-saving strategies to guide decision making. As well as cost efficiencies, the benefits of introducing detachable LDSS include the wide-scale potential to reduce harm while requiring minimal change to service users' behaviour⁵. Furthermore, a complete switch in equipment available across all NSP providers would reach all PWID, including the most marginalised who may not access services directly (i.e. rely on secondary distribution from peers).

Many analyses are limited by the absence of marginalised groups in research, not just modelling. We have looked into this issue in previous and on-going modelling of the risks associated with recent imprisonment⁷ and people experiencing homelessness⁸, and other modelling considering the range of factors that increase mortality among opioid users⁹. Furthermore, while QALYs can be limited, they can also be used to account for factors such as homelessness and recent incarceration which can reduce the quality of life of PWID¹⁰. Therefore, while we agree with Platt et al. and others⁶ that modelling studies can simplify human behaviour, have a narrow viewpoint and are reliant on the data available, they are still a crucial piece of the jigsaw for intervention implementation and investment.

In response to the research methodology critique, we did not use estimates of syringe coverage for Bristol. Instead, we assumed a stable epidemic (consistent with recent data) with current levels of syringe distribution (HDSS and LDSS) to estimate how much transmission through syringe sharing

would decrease by if the majority of HDSS were swapped with detachable LDSS. On generalisability, the strength and robustness of our results suggest it will be cost saving even if done in pharmacy NSP and other settings. In addition, static NSP is still offered in various parts of the UK. One of the authors visited several of these during the implementation phase of this project (described below). These visits revealed that not all NSP are operated by dedicated NSP workers and highlighted the need for updated standardised training which is now being developed in collaboration with a specialist social enterprise. Bristol is unusual in that all injecting equipment is delivered through a single contract, making impact easier to assess.

Finally, we support the assertion that successful intervention implementation requires both service user and provider input. Using co-production methods, we worked closely with PWID as co-designers of harm reduction materials to implement our research in a way that supports the uptake of LDSS equipment by NSP and service users¹¹. The materials are freely available to download (https://www.exchangesupplies.org/shopdisp_low_dead_space_needles_and_syringes_what_and_why_booklet.php) and have been widely distributed.

References

1. Platt, L., Harris, M., Sweeney, S. Commentary on Hancock et al. (2020): Low dead space syringes are just one component of an integrated package of care needed to tackle HCV and social exclusion among people who inject drugs, *Addiction*, 115, 4, (714-715), (2020).
2. Hancock E., Ward Z., Ayres R., Neale J., Hussey D., Kesten J. *et al.* Detachable low dead space syringes for the prevention of hepatitis C among people who inject drugs in Bristol, UK: an economic evaluation. *Addiction* 2020; 115: 702– 713.
3. Trickey, A, May, M, Hope, V, Ward, Z, Desai, M, Heinsbroeke, E, Hickman, M, Vickerman, P. Usage of low dead space syringes and association with hepatitis C prevalence amongst people who inject drugs in the UK. *Drug and Alcohol Dependence* 2018; 192: 118-124.
<https://doi.org/10.1016/j.drugalcdep.2018.07.041>Get rights and content
4. Sweeney S, Ward Z, Platt L, Guinness L, Hickman M, Hope V, et al. Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs. 2019; 114 (3):560-570.
5. Kesten J. M, Ayres R, Neale J, Clark J, Vickerman P, Hickman M. *et al.* Acceptability of low dead space syringes and implications for their introduction: a qualitative study in the west of England. *Int J Drug Policy* 2017; 39: 99– 108.
6. Pearson M, Monks T, Gibson A, Allen M, Komashie A, Fordyce A, Harris-Golesworthy F, Pitta MA, Brailsford S, Stein K. Involving patients and the public in healthcare operational research—The challenges and opportunities. *Operations Research for Health Care*, 2013 2, 4, 86-89
<https://doi.org/10.1016/j.orhc.2013.09.001>
7. Stone, J, Martin, NK, Hickman, M, Hutchinson, SJ, Aspinall, E, Taylor, A, Munro, A, Dunleavy, K, Peters, E, Bramley, P, Hayes, PC. Modelling the impact of incarceration and prison-based HCV (HCV)

treatment on HCV transmission among people who inject drugs in Scotland. *Addiction*, 2017 112, 7
<https://doi.org/10.1111/add.13783>

8. Ward, Z, Campbell, L, Surey, J, Platts, S, Glass, R, Hickman, M, Story, A, Vickerman, P. The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UK. *Journal of Antimicrobial Chemotherapy*, 2019 74, Issue Supplement_5, November 2019, v5–v16,
<https://doi.org/10.1093/jac/dkz451>.

9. Degenhardt, L, Grebely, J, Stone, J, Hickman, M, Vickerman, P, Marshall, BDL, Bruneau, J, Altice, FL, Henderson, G, Rahimi-Movaghar, A, Larney, S. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. *Lancet* 2019; 394: 1560–79
[https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736\(19\)32229-9.pdf](https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(19)32229-9.pdf)

10. Lewer D, Aldridge RW, Menezes D, et al. Health-related quality of life and prevalence of six chronic diseases in homeless and housed people: a cross-sectional study in London and Birmingham, England. *BMJ Open* 2019;9:e025192. doi: 10.1136/bmjopen-2018-025192.

11. Deborah Hussey, Zoe Trinder-Widdess, Cassie Dee, Darren Bagnall, Tatty Bojangles and Joanna May Kesten, Co-design of harm reduction materials for people who inject drugs to implement research findings. *Harm Reduction Journal* 2019 10.1186/s12954-019-0300-z, 16, 1.